Breast Cancer
Conditions
Keywords
Breast cancer, Quality Of Life, Women, Partner
Brief summary
* Selection of patient and preparation of questionnaires * Presentation of the study by the doctor * Verbal consent of participants (patient and Partner) * Delivery of booklets * Response to documents (questionnaires and written consent) at home, send by mail
Detailed description
1. Before consultation : Selection of patients according to inclusion criteria by persons in charge and preparation of inclusion file 2. During the consultation : * Presentation of the study by the investigator * The investigator signs the information note and give two file to the patient (1 for her and 1 for her Partner : both contains 1 information note signed by the investigator, 1 questionnaire and 2 stamped envelopes * Finally, the investigator fill-in the medical form and send the original to the university (université de Lille 3) 3. At home : * Signature of the information note and the participation consent form * Patients and Partner responds to their questionnaire (including socio-demographic questionnaire) * They send the documents thanks to stamped envelopes: 1. They send information note to the medical center 2. They send the questionnaires to the university
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* \>18 years old (patient and partner) * \<45 years old (patient) * Patient with a non metastatic breast cancer * Patient treated or previously treated by chemotherapy * Patient and her Partner live together for at least 6 months when they complete the questionnaires.
Exclusion criteria
* Patient or partner with psychiatric trouble * Native language other than french
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psychometric validation of a questionnaire in Young patients and their partners | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Compare convergent and or divergent dimensions with patients and theirs partners | 1 year |
| Compare responses of participants according to treatment/ surveillance period | 1 year |
Countries
France
Contacts
Centre Oscar Lambret